Technological Advances That Herald A Renaissance in Peptide Drug Discovery

October 15, 2020 11:00 AM - 12:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/15/2020 11:00:56 AM 10/15/2020 12:00:56 PM Technological Advances That Herald A Renaissance in Peptide Drug Discovery

This forum will cover the area of therapeutic peptides and provide historical perspectives including the ups and downs of the field, current development trends, and future directions. We’ll discuss the role of artificial intelligence and machine learning in expanding the landscape of peptide drug discovery opportunities. And we’ll present a case study on targeting Pannexin 1 channels in disease. Questions are welcomed throughout the presentations and panel discussion.

Sponsored by the MassBio Drug Discovery forum working group.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Webinar, click "live-stream" button to view

This forum will cover the area of therapeutic peptides and provide historical perspectives including the ups and downs of the field, current development trends, and future directions. We’ll discuss the role of artificial intelligence and machine learning in expanding the landscape of peptide drug discovery opportunities. And we’ll present a case study on targeting Pannexin 1 channels in disease. Questions are welcomed throughout the presentations and panel discussion.

Sponsored by the MassBio Drug Discovery forum working group.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Chief Business Officer, Nuritas
Arthur Hiller is a Boston-based biopharma executive and currently Chief Business Officer at Nuritas (http://www.nuritas.com), a global leader in applying artificial intelligence to discover and synthesize new drugs based on naturally-occurring bioactive peptides. His career spans more than 35 years of experience across a wide range of functional areas and sectors of the life sciences and healthcare technology industry, including senior leadership roles in setting strategy, building Commercial Operations, launching products, new product development, sales management, and corporate development. Over the last decade, he has been CEO of two early stage companies in the areas of drug discovery and cardiovascular medical devices, and Chief Business Officer of an emerging digital health technology company. Earlier in his career, he held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies. He also served as Senior Vice President, Business Development for Merck-Medco Managed Care, where he focused his efforts on the conceptualization and execution of numerous alliances with pharmaceutical manufacturers to support and expand Merck-Medco disease management programs. Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University, serves in Advisory Board and mentoring capacities for a wide range of start-up and early stage companies in the Boston area.